312 related articles for article (PubMed ID: 27655283)
81. Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery.
Zhang T; Watson DG; Wang L; Abbas M; Murdoch L; Bashford L; Ahmad I; Lam NY; Ng AC; Leung HY
PLoS One; 2013; 8(6):e65880. PubMed ID: 23823321
[TBL] [Abstract][Full Text] [Related]
82. Mass spectrometric based approaches in urine metabolomics and biomarker discovery.
Khamis MM; Adamko DJ; El-Aneed A
Mass Spectrom Rev; 2017 Mar; 36(2):115-134. PubMed ID: 25881008
[TBL] [Abstract][Full Text] [Related]
83. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
[TBL] [Abstract][Full Text] [Related]
84. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
85. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
86. Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors.
Liu Z; Yin P; Amathieu R; Savarin P; Xu G
Anal Bioanal Chem; 2016 Nov; 408(27):7641-7649. PubMed ID: 27614981
[TBL] [Abstract][Full Text] [Related]
87. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
[TBL] [Abstract][Full Text] [Related]
88. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.
Sikora K; Bedin C; Vicentini C; Malpeli G; D'Angelo E; Sperandio N; Lawlor RT; Bassi C; Tortora G; Nitti D; Agostini M; Fassan M; Scarpa A
Int J Biol Markers; 2015 Feb; 30(1):e136-41. PubMed ID: 24832178
[TBL] [Abstract][Full Text] [Related]
89. Advances in pancreatic cancer research: moving towards early detection.
He XY; Yuan YZ
World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
[TBL] [Abstract][Full Text] [Related]
90. Biomarkers screening between preoperative and postoperative patients in pancreatic cancer.
Li P; Yang J; Ma QY; Wu Z; Huang C; Li XQ; Wang Z
Asian Pac J Cancer Prev; 2013; 14(7):4161-5. PubMed ID: 23991970
[TBL] [Abstract][Full Text] [Related]
91. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
Caputo D; Caracciolo G
Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
[TBL] [Abstract][Full Text] [Related]
92. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.
Chen J; Wu W; Chen L; Zhou H; Yang R; Hu L; Zhao Y
Pancreatology; 2013; 13(3):290-7. PubMed ID: 23719603
[TBL] [Abstract][Full Text] [Related]
93. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
94. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
Jenkinson C; Elliott V; Menon U; Apostolidou S; Fourkala OE; Gentry-Maharaj A; Pereira SP; Jacobs I; Cox TF; Greenhalf W; Timms JF; Sutton R; Neoptolemos JP; Costello E
J Proteomics; 2015 Jan; 113():400-2. PubMed ID: 25316052
[TBL] [Abstract][Full Text] [Related]
95. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
96. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
[TBL] [Abstract][Full Text] [Related]
97. Untargeted metabolomics reveals potential plasma biomarkers for diagnosis of primary aldosteronism using liquid chromatography-mass spectrometry.
Song JJ; Cai J; Ma WJ; Lou Y; Bian J; Zhao B; She X; Liu XN
Biomed Chromatogr; 2024 Jun; 38(6):e5855. PubMed ID: 38442715
[TBL] [Abstract][Full Text] [Related]
98. Relative quantification of serum proteins from pancreatic ductal adenocarcinoma patients by stable isotope dilution liquid chromatography-mass spectrometry.
Wehr AY; Hwang WT; Blair IA; Yu KH
J Proteome Res; 2012 Mar; 11(3):1749-58. PubMed ID: 22264027
[TBL] [Abstract][Full Text] [Related]
99. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
100. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
